


CLAIMS:

1. A chemical compound represented by general formula (I)



or a pharmaceutically acceptable salt thereof, wherein

R^0 , R^m and R^p independently of each other represent
hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;
with the proviso that not all three of R^0 , R^m and R^p represent hydrogen;

R^2 , R^3 , R^4 and R^5 independently of each other represent
hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;

- with the proviso that the compound is not
N-(3-Trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-
urea.

2. The compound of claim 1, wherein

R^0 represents hydrogen;
 R^m represents hydrogen; and
 R^p represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

3. The compound of claim 1, wherein

R^0 represents hydrogen;
 R^p represents hydrogen; and
 R^m represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

4. The compound of any one of claims 1-3, wherein

R^3 , R^4 and R^5 represent hydrogen; and
 R^2 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

5. The compound of any one of claims 1-3, wherein
 R^2 , R^4 and R^5 represent hydrogen; and
 R^3 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
- 5 6. The compound of any one of claims 1-3, wherein
 R^2 , R^3 and R^5 represent hydrogen; and
 R^4 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
7. The compound of any one of claims 1-3, wherein
10 R^2 and R^5 represent hydrogen; and
 R^3 and R^4 independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
8. The compound of any one of claims 1-3, wherein
15 R^2 and R^4 represent hydrogen; and
 R^3 and R^5 independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
9. The compound of claim 1, being
20 *N*-(4-Chloro-3-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3-Trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(4-Chloro-3-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
25 *N*-(3,5-Dichloro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Difluoro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3-Trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-5-yl]-urea;
30 *N*-(4-Chloro-3-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Dichloro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Difluoro-phenyl)-*N'*-[4'-fluoro-2-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
35 *N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

- N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 5 *N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 10 *N*-(2-Bromo-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Bromo-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Bromo-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Fluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- 15 *N*-(2-Fluoro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Fluoro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Fluoro-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Bromo-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 20 *N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3,5-Dichloro-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 25 *N*-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;
- N*-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-
- 30 biphenyl-4-yl]-urea;
- N*-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
- 35 *N*-(3,5-Difluoro-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3-Bromo-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(4-Chloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

N- (4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
or a pharmaceutically acceptable salt thereof.

5 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1-9, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

10 11. The use of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to the blockade of chloride channels.

15

12. The use according to claim 11, wherein the disease, disorder or condition responsive to the blockade of chloride channels is a bone metabolic disease, an osteoclast related bone disease, or a disease, disorder or condition that is responsive to inhibition of angiogenesis.

20

13. A method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to the blockade of chloride channels, which method comprises the step of administering to such a living animal body in need

25 thereof a therapeutically effective amount of a compound according to any one of the claims 1-9, or a pharmaceutically acceptable salt thereof.